Vitiligo in a Patient Treated with Interferon Alpha-2a for Behcet's Disease

被引：4
|
作者：
Guney, Esra [1 ]
Akcali, Gulunay [1 ]
Akcay, Betul Ilkay [1 ]
Unlu, Cihan [1 ]
Erdogan, Gurkan [1 ]
Bozkurt, Tahir Kansu [1 ]
Bayramlar, Huseyin [1 ]
机构：
[1] Umraniye Res & Educ Hosp, Ophthalmol Clin, Istanbul, Turkey
来源：
CASE REPORTS IN MEDICINE | 2012年 / 2012卷
关键词：
D O I：
10.1155/2012/387140
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Behcet's disease (BD) and vitiligo are diseases of unknown etiology. Interferon (IFN) alpha therapy is commonly used in Behcet uveitis. Interferon treatment in various diseases have also been observed causing certain autoimmune diseases such as vitiligo because of its immunomodulatory activity. The association between IFN therapy and vitiligo has been reported in the literature. We report a 21-year-old man with BD in whom vitiligo occurred during IFN treatment. To the best of our knowledge, this is the first reported case of such an association.
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Results of Interferon Alpha-2a Therapy in Patients with Behcet's Disease
    Yalcindag, F. Nilufer
    Uzun, Aslihan
    JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, 2012, 28 (04) : 439 - 443
  • [2] ADAMANTIADES-BEHCET DISEASE - TREATMENT WITH SYSTEMIC RECOMBINANT INTERFERON ALPHA-2A
    ZOUBOULIS, CC
    TREUDLER, R
    ORFANOS, CE
    HAUTARZT, 1993, 44 (07): : 440 - 445
  • [3] Interferon Alpha-2a Therapy in Patients with Refractory Behcet Uveitis
    Hasanreisoglu, Murat
    Cubuk, Mehmet Ozgur
    Ozdek, Sengul
    Gurelik, Gokhan
    Aktas, Zeynep
    Hasanreisoglu, Berati
    OCULAR IMMUNOLOGY AND INFLAMMATION, 2017, 25 (01) : 71 - 75
  • [4] Interferon alpha-2a treatment for refractory Behcet uveitis in Korean patients
    Ji Hwan Lee
    Christopher Seungkyu Lee
    Sung Chul Lee
    BMC Ophthalmology, 18
  • [5] Interferon alpha-2a treatment for refractory Behcet uveitis in Korean patients
    Lee, Ji Hwan
    Lee, Christopher Seungkyu
    Lee, Sung Chul
    BMC OPHTHALMOLOGY, 2018, 18
  • [6] Focal epithelial hyperplasia treated with interferon alpha-2a
    Köse, O
    Akar, A
    Safali, M
    Tastan, HB
    Kurumlu, Z
    Gür, AR
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2001, 12 (02) : 111 - 113
  • [7] Safety of Interferon Alpha-2a in Patients with Severe Ophthalmic Behcet's Disease: Response to Bielefeld et al.'s Letter
    Ghembaza, Mohammed El Amine
    Lounici, Ali
    OCULAR IMMUNOLOGY AND INFLAMMATION, 2018, 26 (05) : 793 - 794
  • [8] INTERIM ANALYSIS OF THE CLINICAL TRIAL INCYTOB (INTERFERON ALPHA-2A VERSUS CYCLOSPORINE A FOR THE TREATMENT OF SEVERE OCULAR BEHCET'S DISEASE)
    Deuter, Christoph
    Xenitidis, Theodoros
    Schoenfisch, Birgit
    Zierhut, Manfred
    Koetter, Ina
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2010, 28 (04) : S151 - S151
  • [9] Anti-interferon alpha antibodies and autoantibodies in patients with Behçet’s disease uveitis treated with recombinant human interferon alpha-2a
    Özlem Aydinoglu-Candan
    Bilge Araz-Erşan
    Ahmet Gul
    Selim Badur
    Ilknur Tugal-Tutkun
    Graefe's Archive for Clinical and Experimental Ophthalmology, 2015, 253 : 457 - 465
  • [10] Anti-interferon alpha antibodies and autoantibodies in patients with Beh‡et's disease uveitis treated with recombinant human interferon alpha-2a
    Aydinoglu-Candan, Ozlem
    Araz-Ersan, Bilge
    Gul, Ahmet
    Badur, Selim
    Tugal-Tutkun, Ilknur
    GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2015, 253 (03) : 457 - 465
12345